Literature DB >> 1637251

The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology.

N C Andreasen1, M Flaum, S Arndt.   

Abstract

The Comprehensive Assessment of Symptoms and History was developed for research studies of schizophrenia spectrum conditions and affective spectrum conditions. It is designed to provide a comprehensive information base concerning current and past signs and symptoms, premorbid functioning, cognitive functioning, sociodemographic status, treatment, and course of illness. Because the information base is broad, it is not wedded to a specific diagnostic system but rather permits clinicians and investigators to make diagnoses using a wide range of systems, including Research Diagnostic Criteria, DSM-III, DSM-III-R, and the International Classification of Diseases. Given the fact that disorders in psychiatry are not defined at the etiological or pathophysiological level, diagnostic criteria are prone to ongoing revision as our knowledge base changes. Research strategies suggest that investigators should maintain a flexible database to permit them to adapt to changes in diagnostic systems, to do comparative nosological studies, and, ultimately, to develop new diagnostic systems based on knowledge concerning the underlying neurobiological nature of disorders. Because it provides a comprehensive information base, the Comprehensive Assessment of Symptoms and History facilitates research of this type. Extensive developmental work has been done with the Comprehensive Assessment of Symptoms and History, including interrater and test-retest reliability studies, validity studies, training programs, and data entry programs.

Entities:  

Mesh:

Year:  1992        PMID: 1637251     DOI: 10.1001/archpsyc.1992.01820080023004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  285 in total

1.  Neural basis of novel and well-learned recognition memory in schizophrenia: a positron emission tomography study.

Authors:  B Crespo-Facorro; A K Wiser; N C Andreasen; D S O'Leary; G L Watkins; L L Boles Ponto; R D Hichwa
Journal:  Hum Brain Mapp       Date:  2001-04       Impact factor: 5.038

2.  Thought, language, and communication deficits and association with everyday functional outcomes among community-dwelling middle-aged and older adults with schizophrenia.

Authors:  Anjana Muralidharan; Anastasia Finch; Christopher R Bowie; Philip D Harvey
Journal:  Schizophr Res       Date:  2017-08-01       Impact factor: 4.939

3.  Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods.

Authors:  Nikie Korver; Piotr J Quee; Heleen B M Boos; Claudia J P Simons; Lieuwe de Haan
Journal:  Int J Methods Psychiatr Res       Date:  2012-03-15       Impact factor: 4.035

4.  Premorbid personality and insight in first-episode psychosis.

Authors:  Maria S Campos; Elena Garcia-Jalon; James K Gilleen; Anthony S David; Victor M D Peralta; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2010-10-25       Impact factor: 9.306

5.  COMT Val158Met-stress interaction in psychosis: role of background psychosis risk.

Authors:  Dina Collip; Ruud van Winkel; Odette Peerbooms; Tineke Lataster; Viviane Thewissen; Marielle Lardinois; Marjan Drukker; Bart P F Rutten; Jim Van Os; Inez Myin-Germeys
Journal:  CNS Neurosci Ther       Date:  2010-11-14       Impact factor: 5.243

6.  MRI brain volume abnormalities in young, nonpsychotic relatives of schizophrenia probands are associated with subsequent prodromal symptoms.

Authors:  Beng-Choon Ho
Journal:  Schizophr Res       Date:  2007-08-29       Impact factor: 4.939

7.  Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls.

Authors:  Suzanne Medema; Roel J T Mocking; Maarten W J Koeter; Frédéric M Vaz; Carin Meijer; Lieuwe de Haan; Nico J M van Beveren; René Kahn; Lieuwe de Haan; Jim van Os; Durk Wiersma; Richard Bruggeman; Wiepke Cahn; Carin Meijer; Inez Myin-Germeys
Journal:  Schizophr Bull       Date:  2015-09-18       Impact factor: 9.306

8.  Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study.

Authors:  Sinan Guloksuz; Lotta-Katrin Pries; Philippe Delespaul; Gunter Kenis; Jurjen J Luykx; Bochao D Lin; Alexander L Richards; Berna Akdede; Tolga Binbay; Vesile Altınyazar; Berna Yalınçetin; Güvem Gümüş-Akay; Burçin Cihan; Haldun Soygür; Halis Ulaş; EylemŞahin Cankurtaran; Semra Ulusoy Kaymak; Marina M Mihaljevic; Sanja Andric Petrovic; Tijana Mirjanic; Miguel Bernardo; Bibiana Cabrera; Julio Bobes; Pilar A Saiz; María Paz García-Portilla; Julio Sanjuan; Eduardo J Aguilar; José Luis Santos; Estela Jiménez-López; Manuel Arrojo; Angel Carracedo; Gonzalo López; Javier González-Peñas; Mara Parellada; Nadja P Maric; Cem Atbaşog Lu; Alp Ucok; Köksal Alptekin; Meram Can Saka; Celso Arango; Michael O'Donovan; Bart P F Rutten; Jim van Os
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

9.  Personality compensates for impaired quality of life and social functioning in patients with psychotic disorders who experienced traumatic events.

Authors:  Lindy-Lou Boyette; Daniëlla van Dam; Carin Meijer; Eva Velthorst; Wiepke Cahn; Lieuwe de Haan; René Kahn; Lieuwe de Haan; Jim van Os; Durk Wiersma; Richard Bruggeman; Wiepke Cahn; Carin Meijer; Inez Myin-Germeys
Journal:  Schizophr Bull       Date:  2014-04-25       Impact factor: 9.306

10.  Grey matter, an endophenotype for schizophrenia? A voxel-based morphometry study in siblings of patients with schizophrenia.

Authors:  Jorien van der Velde; Paula M Gromann; Marte Swart; Lieuwe de Haan; Durk Wiersma; Richard Bruggeman; Lydia Krabbendam; André Aleman
Journal:  J Psychiatry Neurosci       Date:  2015-05       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.